EMA Authorised: Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) (lenalidomide hydrochloride monohydrate) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA authorised Lenalidomide Krka (lenalidomide hydrochloride monohydrate) for several hematologic malignancies, including multiple myeloma, myelodysplastic synd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide Krka (lenalidomide hydrochloride monohydrate)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma;Myelodysplastic Syndromes;Lymphoma, Follicular;Lymphoma, Mantle-Cell. MAH: Krka, d.d., Novo mesto. Decision date: 12/03/2026